Professor Paul Richardson, MD, is Clinical Program Leader and Director of Clinical Research at the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute. Appointed RJ Corman Professor of Medicine at Harvard Medical School in 2012. He has led or co-led the clinical development of major therapies for multiple myeloma including lenalidomide, bortezomib, ixazomib, pomalidomide, daratumumab, elotuzumab, and isatuximab.
Professor Andrew Spencer, MD, is Head of the Malignant Haematology, Transplantation and Cellular Therapy Service at The Alfred Hospital, Professor of Haematology at Monash University and Head of the Myeloma Research Group, all in Melbourne, Australia.
Professor Angela Dispenzieri, MD, is a professor of medicine and of laboratory medicine and pathology at Mayo Clinic. She graduated from Massachusetts Institute of Technology and Albert Einstein College of Medicine. She completed her residency and fellowship in internal medicine, haematology and oncology at Mayo Clinic, where she joined the faculty in 1998.
Professor Simon Harrison is the Director, Centre of Excellence for Cellular Immunotherapy at VCCC and the Peter MacCallum Cancer Centre, Stream Lead for CAR T and ACT services and a clinician scientist in the Sir Peter MacCallum department of Oncology in Melbourne University. He is a leading Australia Myeloma clinician and chair of the Myeloma Scientific Advisory Group at Myeloma Australia.
Professor David Gottlieb, MD, trained in medicine at Sydney and Westmead Hospitals before completing a doctorate in Medicine at the Royal Free Hospital in London under Professor Malcolm Brenner. He returned to Australia in 1990 to take up an academic position with the University of Sydney where he is Professor of Haematology.
Professor Mohamad Hussein, MD, began his academic career at the University of Maryland and later directed the Multiple Myeloma Research Program at Cleveland Clinic. He held senior positions at H. Lee Moffitt Cancer Center and transitioned to industry in 2008, joining Celgene Corporation (now Bristol Myers Squibb), where he ascended to Corporate Vice President. He led their multiple myeloma strategy until retiring in 2019.
